romurtide: a synthetic muramyl dipeptide analog; stimulates chemotactic mobility, phagocytic activity & superoxide production by neutrophils in mice; used for the prophylaxis of leukocytopenia during radiation therapy; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917906 |
| CHEMBL ID | 1908331 |
| CHEBI ID | 32106 |
| SCHEMBL ID | 58789 |
| MeSH ID | M0111948 |
| Synonym |
|---|
| muroctasin |
| romurtide |
| nopia |
| dj-7041 |
| mdp-lys(l18) |
| n-acetylmuramyl-ala-d-isoglutaminyl-nepsilon-stearoyl-lys |
| 78113-36-7 |
| (2s)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid |
| ac-muramyl-ala-d-glu(lys(stearoyl)-oh)-nh2 |
| CHEMBL1908331 |
| SCHEMBL58789 |
| CHEBI:32106 |
| mfcd00871261 |
| (2s)-2-((4r)-4-((2s)-2-((2r)-2-((3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-4-yloxy)propanamido)propanamido)-5-amino-5-oxopentanamido)-6-stearamidohexanoic acid |
| NCGC00521952-01 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Subcutaneous LD50 values were 436 mg/kg for male, 625 mg/kg for female in mice, 761 mg/kg for male, 801 mg/kg for female in rats and more than 200 mg/kg for dogs." | ( Acute toxicity of muroctasin in mice, rats and dogs. Furuhama, K; Iwasaki, T; Ono, Y; Onodera, T, 1988) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose (TDNM) was found to be more effective in producing regression of transplantable line-10 tumours than 6,6'-di-O-mycoloyl-alpha,alpha-trehalose (TDM) when combined with 6-O-stearoyl muramyldipeptide (L18-MDP)." | ( Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues. Azuma, I; Hasegawa, A; Ishida, H; Kiso, M; Saiki, I; Saito, S, 1988) | 0.27 |
Romurtide was far more potent than MDP in induction of IL-1, IL-6 and TNF. The number of platelets was also increased significantly with repeated dosing of romurtide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The number of platelets was also increased significantly in monkeys with repeated dosing of romurtide." | ( Stimulatory effect of romurtide on hematopoiesis in monkeys. Akahane, K; Nakajima, R; Osada, Y; Sekiguchi, M; Yshida, Y, 1991) | 0.28 |
| " It is concluded that muroctasin is effective as well as useful on the restorative activities against leukopenia in lung cancer patients after cancer chemotherapy, with the optimal daily dosage of 200 micrograms for six times by subcutaneous injections through phase II and phase III clinical cooperative studies in Japan." | ( [Muramyl dipeptide derivative and its clinical application]. Tsubura, E, 1989) | 0.28 |
| " A comparative study of parent MDP and MDP-Lys(L18) in relation to the protection against infection with various pathogens revealed the same spectrum of antiinfectious activity, but a different potency: the greater strength of MDP-Lys(L18) was demonstrated both by the smaller influence of bacterial inoculum size on its activity and by the smaller minimal dosage required for inducing significant activity." | ( Stimulation of non-specific resistance to infection by muroctasin. Osada, Y; Otani, T; Une, T, 1988) | 0.27 |
| " The drug was subcutaneously administered to 102 cancer patients in a single doses of 200 or 400 micrograms, and each dosage was given either every day for 6 days or every other day over a 5-day period." | ( Restorative activity of muroctasin on leukopenia associated with anticancer treatment. Fukuoka, M; Masaoka, T; Niitani, H; Nishikawa, H; Nomura, T; Okawa, T; Osamura, S; Ota, K; Tanaka, M; Tsubura, E, 1988) | 0.27 |
| " Its high potency was confirmed by the smaller influence of inoculum size and particularly small value of the minimum dosage required for inducing protective activity." | ( Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine. Azuma, I; Matsumoto, K; Ogawa, H; Osada, Y; Otani, T; Une, T, 1983) | 0.27 |
| " Dose-response study indicated that romurtide was far more potent than MDP in induction of IL-1, IL-6 and TNF." | ( Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Chiba, T; Hayashi, H; Hida, S; Hiyama, Y; Onozaki, K; Oomoto, Y; Suzuki, K; Takii, T; Torii, K, ) | 0.13 |
| " Subsequently, dosage at 100 micrograms/animal/d for 8 consecutive days was initiated in separate groups of animals immediately after 1 Gy total body x-irradiation." | ( Enhancement of platelet recovery in X-irradiated guinea pigs by romurtide, a synthetic muramyl dipeptide derivative. Namba, K; Osada, Y; Otani, T, 1994) | 0.29 |
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 17.7828 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID250811 | Effect of compound on secretion of Interleukin-2 treated with bone marrow-derived dendritic cells in presence of lipopolysaccharide | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID250792 | Effect of compound on secretion of Interleukin-2 treated with bone marrow-derived dendritic cells in absence of lipopolysaccharide | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID251206 | In vitro stimulatory effect on increased rate of allogenic CTL cytotoxicity on P815 cells mediated by BMDC in presence of LPS | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID251207 | Effect of compound (10e-6 mol/L) on rate of proliferation of murine splenocytes in absence of concanavalin A compared to control | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID251211 | Effect of compound (10e-6 mol/L) on rate of proliferation of murine splenocytes in presence of concanavalin A compared to control | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID249974 | In vitro stimulatory effect on specific release of allogenic CTL cytotoxicity on P815 cells mediated by BMDC in absence of LPS | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID251205 | In vitro stimulatory effect on increased rate of allogenic CTL cytotoxicity on P815 cells mediated by BMDC in absence of LPS | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID244535 | Increased inhibitory ratio against P388 mice tumor cells compared to control | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| AID249976 | In vitro stimulatory effect on specific release of allogenic CTL cytotoxicity on P815 cells mediated by BMDC in presence of LPS | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 53 (54.08) | 18.7374 |
| 1990's | 36 (36.73) | 18.2507 |
| 2000's | 7 (7.14) | 29.6817 |
| 2010's | 2 (2.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (9.90%) | 5.53% |
| Reviews | 10 (9.90%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 81 (80.20%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||